Product Center
The Phase I Clinical Launch Meeting of the 23-Valent Pneumococcal Polysaccharide Vaccine Was Successfully Held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24
- Views:
(Summary description)The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
The Phase I Clinical Launch Meeting of the 23-Valent Pneumococcal Polysaccharide Vaccine Was Successfully Held
(Summary description)The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24 16:08
- Views:
The golden autumn is refreshing, and the fruits are fragrant. In this harvest season, we usher in a promising new chapter. The sound of the song is far away, and the Qi River is flowing. In Qi County, Hebi City, Henan Province, a famous historical and cultural city in China, the launch meeting of the Phase I clinical research project of the 23-valent pneumococcal polysaccharide vaccine, jointly developed by Ab&B Bio-Tech Co., Ltd. JS and Beijing Huaan Kechuang Biotechnology Co., Ltd., was successfully held.
The kick-off meeting was presided over by Wang Yanxia, Deputy Director of the Henan Provincial Center for Disease Control and Prevention. Leaders such as Guo Wanshen, Director of the Henan Provincial Center for Disease Control and Prevention, and Zhu Jiangbo, Deputy Mayor of Qi County, attended the kick-off meeting and delivered important speeches. Mr. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd. JS, gave a detailed introduction to the company's development and vaccine overview.
The kick-off meeting organized detailed training and drills for this clinical program. Dr. Shi Weiwei from Beijing Huaan Kechuang Biotechnology Co., Ltd. conducted the 23-valent pneumococcal polysaccharide vaccine researcher's manual training; Mr. Wang Yanxia, Deputy Director of the Henan Provincial Center for Disease Control and Prevention, conducted the quality management standard for drug clinical trials (GCP) and the clinical trial program training for this project; Mr. Zhang Wei from the Henan Provincial Center for Disease Control and Prevention explained the clinical quality control of vaccines and related standard operating procedures; Mr. Guo Qi, project manager of Beijing Zhongsheng Hengyi Pharmaceutical Technology Co., Ltd., a clinical supervision agency, conducted training on clinical research operation procedures.
At the Qixian County Center for Disease Control and Prevention, the participants took part in the on-site simulation exercise and completed a series of tasks such as on-site simulated reception, informed consent, sample collection, physical examination and inquiry, random allocation, vaccination, and post-vaccination observation by functional area. Adhering to the principle of "all for the subjects" during the exercise, they always followed the requirements of the regulations to carry out tasks carefully, meticulously, and comprehensively, and identified and corrected problems in a timely manner. Through the on-the-spot simulation drills, it was ensured that every tester could complete the clinical trial skillfully and efficiently.
"When the winds are favorable, set sail and brave the waves." Ab&B Bio-Tech Co., Ltd. JS will continue to uphold the work spirit of being rigorous, serious, pragmatic, self-disciplined, and always persisting in struggle. We will seek well-being!
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us